Source: http://federal.elaws.us/fr/12/11/2019/2019-26682
Timestamp: 2020-06-03 07:26:15
Document Index: 629433866

Matched Legal Cases: ['art 516', 'art 516', '§\u2009516', '§\u2009516', '§\u2009516', '§\u2009516', '§\u2009516']

2019-26682. Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Reporting Associated With Designated New Animal Drugs for Minor Use and Minor Species, Federal Register
Home » 2019 Issues » 84 FR (12/11/2019) » 2019-26682. Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Reporting Associated With Designated New Animal Drugs for Minor Use and Minor Species
2019-26682. Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Reporting Associated With Designated New Animal Drugs for Minor Use and Minor Species
Fax written comments on the collection of information by January 10, 2020.
To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, Fax: 202-395-7285, or emailed to oira_submission@omb.eop.gov. All comments should be identified with the OMB control number 0910-0605. Also include the FDA docket number found in brackets in the heading of this document.
Reporting Associated With Designated New Animal Drugs for Minor Use and Minor Species—21 CFR Part 516
OMB Control Number 0910-0605—Extension
The Minor Use and Minor Species (MUMS) Act (Pub. L. 108-282) amended the Federal Food, Drug, and Cosmetic Act to authorize FDA to establish new regulatory procedures intended to make more medications legally available to veterinarians and animal owners for the treatment of minor animal species as well as uncommon diseases in major animal species. This legislation provides incentives designed to help pharmaceutical companies overcome the financial burdens they face in providing limited-demand animal drugs. These incentives are only available to sponsors whose drugs are “MUMS-designated” by FDA. Minor use drugs are drugs for use in major species (e.g., cattle, horses, swine, chickens, turkeys, dogs, and cats) that are needed for diseases that occur in only a small number of animals either because they occur infrequently or in limited geographic areas. Minor species are all animals other than the major species (e.g., zoo animals, ornamental fish, parrots, ferrets, and guinea pigs). Some animals of agricultural importance are also minor species. These include animals such as sheep, goats, catfish, and honeybees. Participation in the MUMS program is completely optional for drug sponsors, so the associated reporting only applies to those sponsors who request and are subsequently granted “MUMS designation.”
Our regulations in 21 CFR part 516 specify the criteria and procedures for requesting MUMS designation as well as the annual reporting requirements for MUMS designees. Section 516.20 provides requirements on the content and format of a request for MUMS-drug designation; § 516.26 provides requirements for amending MUMS-drug designation; § 516.27 provides for change in sponsorship of MUMS-drug designation; § 516.29 provides for termination of MUMS-drug designation; § 516.30 contains the requirements for annual reports from sponsor(s) of MUMS-designated drugs; and § 516.36 sets forth consequences for insufficient quantities of MUMS-designated drugs.
Description of Respondents: The respondents to this information collection are pharmaceutical companies that sponsor new animal drugs.
In the Federal Register of June 12, 2019 (84 FR 27333), FDA published a 60-day notice requesting public comment on the proposed collection of Start Printed Page 67746information. No comments were received.
Table 1—Estimated Annual Reporting 1
516.20; content and format of MUMS request 15 5 75 16 1,200
516.26; requirements for amending MUMS designation 3 1 3 2 6
516.27; change in sponsorship 1 1 1 1 1
516.29; termination of MUMS designation 2 1 2 1 2
516.30; requirements of annual reports 15 5 75 2 150
516.36; insufficient quantities 1 1 1 3 3
The burden estimate for this reporting requirement was derived in our Office of Minor Use and Minor Species Animal Drug Development by extrapolating the investigational new animal drug/new animal drug application reporting requirements for similar actions by this same segment of the regulated industry and from previous interactions with the minor use/minor species community, and has not changed since the last OMB approval.
[FR Doc. 2019-26682 Filed 12-10-19; 8:45 am]
2019-26682
67745-67746 (2 pages)
Docket No. FDA-2016-N-2474
2019-26682.pdf